Dr. Lane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3000
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2012- Brigham and Women's HospitalResidency, Internal Medicine, 2006 - 2008
Washington University in St. Louis School of MedicineClass of 2006
Certifications & Licensure
MA State Medical License 2008 - 2025- American Board of Internal Medicine Hematology
Clinical Trials
- SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Start of enrollment: 2014 Sep 01
- SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Start of enrollment: 2017 Jun 26
- Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Start of enrollment: 2018 Aug 23
Publications & Presentations
PubMed
- 1778 citationsNext-generation characterization of the Cancer Cell Line EncyclopediaMahmoud Ghandi, Franklin W. Huang, Judit Jané-Valbuena, Gregory V. Kryukov, Christopher Lo
Nature. 2019-05-08 - 297 citationsA targeted mutational landscape of angioimmunoblastic T-cell lymphomaOreofe O. Odejide, Oliver Weigert, Andrew A. Lane, Dan Toscano, Matthew A. Lunning
Blood. 2014-02-27 - 1401 citationsSingle-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors.Alexandra-Chloé Villani, Rahul Satija, Gary Reynolds, Siranush Sarkizova, Karthik Shekhar
Science. 2017-04-21
Abstracts/Posters
- Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor P...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
New Target for Potential Leukemia TherapyMay 8th, 2024- Leukemia Relapse Could Be Prevented by Disrupting Immune Signaling MechanismMay 8th, 2024
Stemline Therapeutics Announces That Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary EndpointOctober 31st, 2017- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
